CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
ongoing trials trial from www.clinicaltrials.gov

A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age (VX21-121-105)

  • Year: 2024
  • Date: December 30, 2023
  • Author:
Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment

Participants

Cystic Fibrosis-related Diabetes|Cystic Fibrosis - 18 Years and older   (Adult, Older Adult)

Interventions

Drug: Empagliflozin|Other: Placebo Control

Outcome measures

Feasibility, safety, tolerability

Keywords: Empagliflozin; SGLT2 inhibitors; Hypoglycemic Agents; pharmacological_intervention;